| Name | Title | Contact Details |
|---|
Fewer than 50% of Sleep Apnea patients stick with a CPAP solution – including us. So we decided to do something about it. Not sleeping sucks. Not sleeping and spending a fortune on CPAP devices that leak, fall off or leave marks on your face sucks even worse. That`s why we invented the DreamPort Sleep Solution – the world`s first-ever maskless CPAP device. The result is the smallest, lightest, most ergonomically accommodating CPAP solution on the market – a device that fits comfortably and doesn`t restrict your movement – enabling patients to get a better night`s sleep. Our goal is simple – to make the best bleeping CPAP products on the planet. We won`t stop until every sleep apnea patient is sleeping like a baby.
Through advancing research, observing natural behavior, and listening to our customers, Medela turns science into care while nurturing health for generations. Medela supports millions of moms, babies, patients, and healthcare professionals in more than 100 countries all over the world. As the healthcare choice for more than 6 million hospitals and homes across the globe, Medela provides the leading research-based breast milk feeding and baby products, healthcare solutions for hospitals, and clinical education.
Vittamed is an early stage medical technology company developing innovative ultrasound-based non-invasive neuro diagnostic and monitoring technologies including the measurement of absolute value of intracranial pressure, real time cerebral blood flow autoregulation and intracranial volumetric wave monitoring.
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe
Ats Medical Services Inc is a Rockford, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.